Petrelintide
An amylin analog as an alternative to GLP-1 receptor agonists for weight management
Petrelintide is an investigational long-acting amylin analog for once-weekly subcutaneous administration that has been designed with chemical and physical stability at neutral pH, minimizing fibrillation and allowing for co-formulation with other peptides.
Amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin analogs have been shown to increase satiety by a direct effect on the amylin receptor and by restoring sensitivity to the hormone leptin. This is in contrast to GLP-1 receptor agonists that primarily lower body weight by reducing appetite.
Current clinical or preclinical data suggest a potential for long-acting amylin analogs to deliver a reduction in body weight that is comparable to GLP-1 receptor agonists but with improved tolerability for a better patient experience and a high-quality weight loss through the preservation of lean muscle.
- PROGRAM Petrelintide
- Phase 1
Development status
We have evaluated petrelintide in a Phase 1b multiple ascending dose (MAD) clinical trial.
In Part 1 of this Phase 1b MAD trial, low doses of 0.6 mg and 1.2 mg petrelintide administered weekly over six weeks showed an average weight loss of -5.3% and -5.1%, respectively. Petrelintide was well-tolerated with no serious or severe treatment-emergent adverse events and no withdrawals from the trial. All gastrointestinal adverse events reported were mild. These results were reported in 2023.
Part 2 of the MAD trial explored significantly higher doses of petrelintide over a longer duration of 16 weeks. These results are expected to be presented at an upcoming scientific congress.
We are planning a Phase 2b clinical program to further evaluate petrelintide in people living with overweight or obesity.
Petrelintide is an investigational compound whose safety and efficacy have not been evaluated or approved for marketing by any regulatory authority.
Related scientific publications
All scientific publications-
Petrelintide (ZP8396) selectively reduces intake of high fat diet in DIO rats
-
Petrelintide (ZP8396) significantly reduces fat mass while preserving lean mass in DIO rats
-
Novel once-weekly amylin analog petrelintide (ZP8396) is well tolerated with improved GI tolerability after multiple dosing
-
Safety, Tolerability, and Clinical Effects of ZP8396, an Amylin Analog: Multiple Ascending Dose Trial
Learn about clinical trials involving petrelintide
Obesity
More about the disease area
Overweight and obesity are associated with more than 220 complications and comorbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuroinflammation.
